Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Boehringer Ingelheim
McKesson
Mallinckrodt
Medtronic

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

LUXIQ Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Luxiq patents expire, and when can generic versions of Luxiq launch?

Luxiq is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in LUXIQ is betamethasone valerate. There are sixty-six drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.

US ANDA Litigation and Generic Entry Outlook for Luxiq

A generic version of LUXIQ was launched as betamethasone valerate by FOUGERA PHARMS INC on December 13th, 2019.

Drug patent expirations by year for LUXIQ
Drug Prices for LUXIQ

See drug prices for LUXIQ

Recent Litigation for LUXIQ

Identify potential future generic entrants

District Court Litigation
Case NameDate
Connetics Corporation v. Pentech Pharmaceuticals Inc2008-04-18
Bone Care International LLC v. Pentech Pharmaceuticals, Inc.2008-02-21
Connetics Corporation v. Pentech Pharmaceuticals, Inc.

See all LUXIQ litigation

Pharmacology for LUXIQ
Synonyms for LUXIQ
(11.beta.,16.beta.)-9.alpha.-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17.alpha.-valerate
(11beta,16beta)-9-fluoro-11,21-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl pentanoate
(2S,10S,11S,13S,15S,17S,1R,14R)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13, 15-trimethyl-5-oxotetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl pe ntanoate
(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl p
(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl pentanoate
[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
1,4-Pregnadiene-11beta,17alpha,21-triol-9alpha-fluoro-16beta-methyl-3,20-dione 17-valerate
12772-60-0
149665-14-5
152M445
2152-44-5
9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione-17-valerate
9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17-valerate
9-Fluoro-11.beta.,21-dihydroxy-16.beta.-methyl-3,20-dioxopregna-1,4-dien-17-yl pentanoate #
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-valerate
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17-valerate
9-fluoro-11beta,21-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl pentanoate
9-fluoro-11beta,21-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl valerate
944728-94-3
9alpha-Fluoro-16beta-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 17-valerate
9alpha-Fluoro-16beta-methylprednisolone 17-valerate
9IFA5XM7R2
AB01274710_02
AB01274710-01
AB2000222
AC1L285F
AKOS015994704
AN-14218
Bedermin
beta-Methasone 17-valerate
beta-Val
Beta-Val (TN)
Betaderm
Betamethason-17-valerate
Betamethasone 17-valerate
Betamethasone 17a-valerate
Betamethasone 17alpha-valerate
BETAMETHASONE VALERATE
Betamethasone Valerate (Betamethasone 17-Valerate)
Betamethasone valerate (Betnovate)
Betamethasone valerate (JP17/USP)
Betamethasone valerate [USAN:BAN:JAN]
Betamethasone valerate [USAN:USP:JAN]
Betamethasone-17-valerate
Betatrex (Salt/Mix)
Betaval
Betnesol V
Betnesol-V
Betneval
Betnovate
Betnovate;Celestone;Betaderm;Luxiq
Betnovateat
Betoid
Bettamousse
Bextasol
BRD-K34032314-001-04-1
C27H37FO6
CAS-2152-44-5
Celestan V
Celestan-V
Celestane V
Celestoderm
Celestoderm V
Celestoderm-V
Celeston valerate
CHEBI:31277
CHEMBL1497
Chlorophytum Borivilanum
D01357
Dermosol
Dermovaleas
DSSTox_CID_2673
DSSTox_GSID_22673
DSSTox_RID_76684
DTXSID7022673
Ecoval 70
EINECS 218-439-3
entanoate
Flubenisolonvalerate
Fuciderm
Gentocin (Salt/Mix)
Gentocin (Veterinary)
KS-1198
LS-118456
Luxiq (TN)
MFCD00867446
MolPort-003-933-651
NCGC00255185-01
NCGC00274064-01
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-, (11beta,16beta)-
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-,(11-beta,16-beta)-
Rinderon V
Rinderon-V (TN)
RL02645
s1690
SCHEMBL7270
SNHRLVCMMWUAJD-SUYDQAKGSA-N
ST075178
Stanoval
Tokuderm
Topagen (Salt/Mix)
Topagen (Veterinary)
Tox21_302288
UNII-9IFA5XM7R2
Valnac
ZINC3882052
Paragraph IV (Patent) Challenges for LUXIQ
Tradename Dosage Ingredient NDA Submissiondate
LUXIQ AEROSOL, FOAM;TOPICAL betamethasone valerate 020934 2007-08-10

US Patents and Regulatory Information for LUXIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
McKinsey
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.